Rafferty Asset Management LLC Sells 7,965 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Rafferty Asset Management LLC has reduced its stake in Thermo Fisher Scientific by 18.4%, selling 7,965 shares and now holding 35,416 shares valued at approximately $17.6 million.
• Insider transactions included the CEO Marc N. Casper selling 10,000 shares for over $5 million and EVP Gianluca Pettiti selling 400 shares for about $192,000, indicating significant insider activity.
• Thermo Fisher Scientific reported Q2 earnings of $5.36 per share, exceeding estimates, with revenue of $10.86 billion, and has set guidance of 5.460-5.510 EPS for Q3 2025.

Rafferty Asset Management LLC lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 18.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 35,416 shares of the medical research company's stock after selling 7,965 shares during the quarter. Rafferty Asset Management LLC's holdings in Thermo Fisher Scientific were worth $17,623,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also added to or reduced their stakes in TMO. Vanguard Group Inc. raised its stake in shares of Thermo Fisher Scientific by 0.7% during the first quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock valued at $16,659,627,000 after acquiring an additional 230,382 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Thermo Fisher Scientific by 4.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock worth $1,455,774,000 after purchasing an additional 115,463 shares during the last quarter. Pictet Asset Management Holding SA lifted its holdings in Thermo Fisher Scientific by 7.2% during the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after buying an additional 193,378 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Thermo Fisher Scientific by 11.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,420,949 shares of the medical research company's stock valued at $1,259,450,000 after buying an additional 257,462 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Thermo Fisher Scientific by 9.8% during the first quarter. Goldman Sachs Group Inc. now owns 2,419,617 shares of the medical research company's stock worth $1,204,002,000 after acquiring an additional 215,232 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the sale, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. This trade represents a 7.99% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 28,896 shares of company stock worth $13,603,438. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Down 0.4%

Shares of NYSE:TMO opened at $488.93 on Wednesday. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The business has a fifty day moving average price of $446.71 and a two-hundred day moving average price of $455.47. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The company has a market capitalization of $184.63 billion, a PE ratio of 28.28, a price-to-earnings-growth ratio of 2.62 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. During the same period in the previous year, the company earned $5.37 earnings per share. The company's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is 9.95%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on TMO. Barclays increased their target price on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research report on Thursday, July 24th. William Blair began coverage on shares of Thermo Fisher Scientific in a research note on Monday, August 18th. They set an "outperform" rating for the company. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target on the stock in a research report on Friday, July 11th. Wall Street Zen lowered Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, August 10th. Finally, UBS Group increased their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a report on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $593.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.